RDY
Dr. Reddy's Laboratories Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$11.97
−0.50%Year over year
Reported trailing growth
- Revenue
- -0.4%
- EBITDA
- -43.3%
- EBIT
- -50.7%
- EPS
- -41.6%
- Free cash flow
- +4.9%
- Operating cash flow
- -22.0%
Forward estimates
Based on analyst estimates
- Revenue
- +3.1%
- EBITDA
- +39.8%
- EPS
- +12.8%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- +3.8%
- EBIT
- -5.1%
- Net income
- +0.0%
- EPS
- -0.2%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026